MISSION VIEJO, CA--(Marketwired - August 31, 2016) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, announced today that it will be presenting at the 2016 Aegis Growth Conference on Thursday, September 22nd at 9:00AM PDT / 12 Noon EDT at the Encore at Wynn in Las Vegas. David C. Cavalier, Chairman and Chief Financial Officer will be giving the presentation and meeting with investors.
Mr. Cavalier will provide an update on Aeolus' development pipeline, including its $118.4 million advanced R & D contract with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the U.S. Department of Health and Human Services. The BARDA contract funds the advanced development of AEOL 10150 ("10150") for the treatment of the pulmonary and delayed effects of acute radiation exposure ("Lung-ARS") following a nuclear detonation or accident. 10150 has demonstrated efficacy in multiple mouse and non-human primate Lung-ARS studies and is being developed under the FDA Animal Rule, which allows the use of animal studies in indications where human efficacy trials are not possible. 10150 is also being developed for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") and for use in oncology to reduce the side effects of radiation therapy for solid tumors. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease with support from the Michael J. Fox Foundation for Parkinson's disease. A third compound, AEOL 20415, is in development for the treatment of infectious diseases.
A webcast of the presentation will be available live on the Company's website at www.aolsrx.com. The presentation will also be archived for viewing after the conference.
About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. AEOL 10150 may have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation in a nuclear event or the treatment of cancer.
AEOL 10150 has performed well in animal safety studies, was well tolerated in two human clinical trials and has demonstrated statistically significant survival efficacy in multiple Lung-ARS studies in animals. Aeolus has received "Orphan Drug" designation for the use of AEOL 10150 in treating Lung ARS and Idiopathic Pulmonary Fibrosis and has an IND on file to allow for human safety testing of the compound in healthy volunteers. AEOL 10150 is also currently in development for use in IPF and as both a therapeutic and prophylactic drug in cancer patients.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of novel compounds, known as metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to develop the compound for the treatment of lung fibrosis, including IPF and as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control in cancer therapy. The Company is also developing AEOL 11114 as a treatment for Parkinson's disease and AEOL 20415 as a treatment for cystic fibrosis and diseases that have developed a resistance to existing antibiotic and anti-viral therapies. For more information, please visit Aeolus's corporate website at www.aolsrx.com.
The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, a potential phase 1 study in healthy normal volunteers, the BARDA Contract, and the expected use of proceeds from the financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' Annual Report on Form 10-K for the year ended September 30, 2015. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.